Article

False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.

Department of Clinical Radiology, Leeds Teaching Hospitals NHS Trust, UK.
Clinical radiology (impact factor: 1.65). 04/2011; 66(4):366-82. DOI:10.1016/j.crad.2010.12.004 pp.366-82
Source: PubMed

ABSTRACT With the increasing utilization of integrated positron-emission tomography/computed tomography (PET/CT) using the glucose analogue 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) in oncological imaging, it is important for radiologists and nuclear medicine physicians to be aware that FDG uptake is not specific for malignancy, as many different physiological variants and benign pathological conditions can also exhibit increased glucose metabolism. Such false-positive FDG uptake often arises outside the area of primary interest and may mimic malignant disease, thereby confounding accurate interpretation of PET/CT studies. With the use of illustrative clinical cases, this article will provide a systematic overview of potential interpretative pitfalls and illustrate how such unexpected findings can be appropriately evaluated.

0 0
 · 
0 Bookmarks
 · 
44 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

accurate interpretation
 
different physiological variants
 
false-positive FDG uptake
 
FDG
 
FDG uptake
 
illustrative clinical cases
 
nuclear medicine physicians
 
oncological imaging
 
PET/CT studies
 
positron-emission tomography/computed tomography
 
radiologists
 
unexpected findings